Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512468 | 0.80 | CYP19A1 (0.37) | CYP19A1 | |
| SCHEMBL512655 | 0.78 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL1226818 | 0.77 | WNT3A (0.36) | — | |
| SCHEMBL1226835 | 0.75 | WNT3A (0.39) | — | |
| SCHEMBL512872 | 0.66 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL511836 | 0.65 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL512672 | 0.64 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL512723 | 0.63 | IDO1 (0.39) | — | |
| SCHEMBL512155 | 0.63 | CYP19A1 (0.42) | CYP19A1 | |
| SCHEMBL1274359 | 0.62 | CYP19A1 (0.35) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-A1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459197-A1 | COMPOUNDS FOR THE REDUCTION OF -AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |